Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
BiVictriX Therapeutics PLC
BVXBiVictriX Therapeutics plc, a biotechnology company, engages in the research and experimental development of pharmaceutical products in the United Kingdom. The company develops Bi-Cygni, a proprietary platform that combines the discovery of novel, cancer-selective twin-antigen pairs or fingerprints with bispecific antibody engineering insights to create anti-cancer therapeutics. Its lead program is BVX001, a first-in-class Bi Cygni antibody drug conjugates to treat acute myeloid leukemia. The company also develops BVX002 for treating ovarian and other solid tumors; and BVX003 for bladder and other solid tumors. The company was formerly known as BiVictriX plc and changed its name to BiVictriX Therapeutics plc in August 2021. BiVictriX Therapeutics plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom. Address: Mereside, Macclesfield, United Kingdom, SK10 4TG
Analytics
Preço Alvo de Wall Street
5 099 GBXRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave BVX
Análise de Dividendos BVX
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos BVX
Avaliação de ações BVX
Relatório BVX
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |